Cytokinetics, Inc develops and commercializes muscle activators and inhibitors to treat diseases. They focus on creating small molecules that impact muscle function and contractility, and some of their drug candidates are currently in Phase III clinical trials for heart failure, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company was founded in 1997 and has its headquarters in South San Francisco, California, and has a strategic partnership with Astellas Pharma.